Advanced age has traditionally been seen as prohibitive for treatments like stem cell transplants and CAR T therapy. This presentation reviews evidence that overall fitness is a crucial factor in reducing non-relapse mortality and that otherwise healthy elderly patients can have successful outcomes after transplant and CAR T-cell therapy.

CAR T therapy (chimeric antigen receptor therapy) is a new treatment strategy that has been shown to improve patient outcomes. In this lecture, Dr. William reviews the steps involved, including T-cell collection, lymphodepleting chemotherapy, reinfusion of T-cells, and follow-up care. Potential side effects and their treatments are discussed as wel

La terapia de Células CAR-T es una nueva terapia para pacientes con mieloma múltiple. Esta presentación explica qué es la terapia de Células CAR-T, cuál es su eficacia para los pacientes con mieloma y los posibles efectos secundarios.

CAR T-cell therapy is an exciting second-line option for patients living with relapsed multiple myeloma. In this presentation, Dr. Ahmed reviews each step in the CAR T process and discusses a number of studies that support its use. Potential side effects are reviewed, and exciting future trends are discussed.

In the years after having a transplant using your own cells (autologous transplant), complications can develop. This presentation describes possible late complications, risk factors for each complication, ways that you can help minimize the risks, and strategies for managing any complications that do occur.

Late effects after an allogeneic transplant (a transplant using donor cells) can affect the physical, psychological, and social well-being of survivors. Dr. Hamilton sheds light on the most common long-term effects and how they can best be managed to minimize complications. She also stresses the importance of ongoing survivorship care to ensure that survivors can live life to the fullest.

Strategies astronauts use to stay fit during space flight can help bone marrow/stem cell transplant and CAR T-cell recipients.